Diltiazem hydrochloride tablet warnings: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Diltiazem}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CARDIZEM (DILTIAZEM HYDROCHLORIDE) TABLET, COA...")
 
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{AK}}
{{CMG}}; {{AE}} {{AK}}


==WARNINGS==


1. '''Cardiac Conduction'''. CARDIZEM prolongs [[AV node]] refractory periods without significantly prolonging sinus node recovery time, except in patients with [[sick sinus syndrome]]. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or [[second-degree AV block|second-]]or [[third-degree AV block]] (six of 1243 patients for 0.48%). Concomitant use of diltiazem with[[ beta-blockers ]]or [[digitalis ]]may result in additive effects on cardiac conduction. A patient with [[Prinzmetal's angina]] developed periods of [[asystole ]](2 to 5 seconds) after a single dose of 60 mg of diltiazem (see  [[Diltiazem hydrochloride tablet adverse reactions|ADVERSE REACTIONS]]).
2. '''Congestive Heart Failure'''. Although diltiazem has a negative [[inotropic ]]effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in [[cardiac index]] nor consistent negative effects on contractility (dp/dt). Experience with the use of CARDIZEM alone or in combination with beta-blockers in patients with impaired ventricular function is very limited. Caution should be exercised when using the drug in such patients.


3. '''Hypotension'''. Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic [[hypotension]].


 
4. '''Acute Hepatic Injury'''. In rare instances, significant elevations in enzymes such as [[alkaline phosphatase]], [[LDH]], [[SGOT]], [[SGPT]], and other phenomena consistent with acute hepatic injury have been noted. These reactions have been reversible upon discontinuation of drug therapy. The relationship to CARDIZEM is uncertain in most cases, but probable in some (see [[Diltiazem hydrochloride tablet  precautions|PRECAUTIONS]]).<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = CARDIZEM (DILTIAZEM HYDROCHLORIDE) TABLET, COATED [BTA PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=461fe23f-4453-4e3f-9621-0e3fda057d14 | publisher =  | date =  | accessdate = 5 March 2014 }}</ref>
 
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = CARDIZEM (DILTIAZEM HYDROCHLORIDE) TABLET, COATED [BTA PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=461fe23f-4453-4e3f-9621-0e3fda057d14 | publisher =  | date =  | accessdate = 5 March 2014 }}</ref>
 


==References==
==References==

Revision as of 15:18, 5 March 2014

Diltiazem
CARDIZEM tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
CARDIZEM LA tablet extended release® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packages
DILTIAZEM HYDROCHLORIDE injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Diltiazem
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

WARNINGS

1. Cardiac Conduction. CARDIZEM prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second-or third-degree AV block (six of 1243 patients for 0.48%). Concomitant use of diltiazem withbeta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS). 2. Congestive Heart Failure. Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dp/dt). Experience with the use of CARDIZEM alone or in combination with beta-blockers in patients with impaired ventricular function is very limited. Caution should be exercised when using the drug in such patients.

3. Hypotension. Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic hypotension.

4. Acute Hepatic Injury. In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and other phenomena consistent with acute hepatic injury have been noted. These reactions have been reversible upon discontinuation of drug therapy. The relationship to CARDIZEM is uncertain in most cases, but probable in some (see PRECAUTIONS).[1]

References

  1. "CARDIZEM (DILTIAZEM HYDROCHLORIDE) TABLET, COATED [BTA PHARMACEUTICALS]". Retrieved 5 March 2014.